“Prostate cancer prevention” (marketing claim)

Marketing claim of «prostate cancer prevention supplements». No guideline frames a primary prostate cancer prevention strategy: SEOM 2024 and AUA 2023 advise only shared decision-making on PSA screening in men aged 50–69 (or from 45 with family history), smoking cessation and obesity control. EFSA has rejected all health claims for lycopene and other carotenoids. The claim drives sales of lycopene, selenium, zinc, saw palmetto extract and combo supplements.

1 drug

Also known as: Prostate protection, Prostate health, Prostate support, Carotenoids for men's health

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

DLycopeneNot recommended · Tetraterpene carotenoid; pigment of tomatoes, rosehip, watermelon and grapefruit; sold as a supplement and as the food colorant E160d; not registered as a medicine by AEMPSLycopene is the flagship supplement in the «tomatoes protect against prostate cancer» narrative. Observational studies in Mediterranean populations did link high tomato intake to lower prostate cancer rates. Randomised controlled trials did not confirm the signal: the FDA systematic review by Kavanaugh 2007 found «very limited evidence», and the Cochrane review by Ilic 2011 did not confirm a risk reduction with lycopene supplements. EFSA rejected all lycopene health claims in 2011 and 2014, including «prostate protection». SEOM 2024 and AUA 2023 do not include lycopene in primary prostate cancer prevention. For men over 50, shared decision-making about PSA screening with a urologist, smoking cessation and obesity control are the relevant actions – not a lycopene supplement.

How to read tiers A–F

Evidence tiers belong to the drug-indication pair, not to the drug as a whole: the same substance can be A for one condition and F for another.

AStrong evidence – first or second line in international guidelines
BRecommended in selected cases
CStudy data contradict each other
DBenefit not proven, no documented harm
FDocumented harm, or risk without benefit